BioAge Labs | Targeting metabolic aging
WEBJun 21, 2024 · BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs
BioAge Labs | Company
WEBBioAge takes a human-centric, data-driven approach to identify the molecular features of healthy aging and reveal the causes of age-related diseases. By targeting aging with a large and mechanistically diverse portfolio of drugs, we will unlock opportunities to treat or even prevent these diseases in entirely new ways.
BioAge Labs | About us - Discovery
WEBKristen leads BIOAGE in its mission to develop a broad pipeline of therapies that target aging in order to increase healthspan and address chronic diseases. Kristen draws from a deep background in aging research and systems biology to develop BIOAGE’s data-driven approach to identify and target the molecular pathways that drive aging.
BioAge Labs | Platform - Discovery
WEBBioAge’s human-first platform identifies novel metabolic aging targets by analyzing proprietary longitudinal human samples and detailed health records spanning 45+ years.
BioAge Labs Announces Pricing of Upsized Initial Public Offering
WEBRICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the pricing of its upsized initial public offering of 11,000,000 ...
Events | BioAge Labs, Inc.
WEBStay up to date with BioAge Labs, Inc.'s investor events.
Presentations | BioAge Labs, Inc.
WEBJun 21, 2024 · View BioAge Labs, Inc.'s investor presentations.
BioAge Labs | About Aging - Discovery
WEBThe BioAge mission is to extend healthy lifespan by developing treatments that target the molecular causes of human aging.
BioAge Announces First Patient Dosed in the STRIDES Phase 2 …
WEBJul 29, 2024 · In mid-2024, BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs.
BioAge Labs | Events - Discovery
WEBApr 29, 2024 · BioAge takes over the NYSE Trading Floor! Thanks to the team at NYSE for helping us continue the celebration of our $170M Series D to bring our lead compound into Phase 2 clinical trials and advance our pipeline.
- Some results have been removed